

Form 62-103F3
Required Disclosure by an Eligible Institutional Investor under Part 4

State if this report is filed to amend information disclosed in an earlier report. Indicate the date of the report that is being amended.

Not applicable.

Item 1 – Security and Reporting Issuer

1.1 State the designation of securities to which this report relates and the name and address of the head office of the issuer of the securities.

This report relates to the common shares (“**Common Shares**”) of McCoy Global Inc. (the “**Reporting Issuer**”). The head office of the Reporting Issuer is located at:

Suite 201, 9910 39th Ave NW
Edmonton, AB
T6E 5H8

1.2 State the name of the market in which the transaction or other occurrence that triggered the requirement to file this report took place.

The transactions that triggered the requirement to file this report took place through the facilities of the Toronto Stock Exchange.

Item 2 – Identity of the Eligible Institutional Investor

2.1 State the name and address of the eligible institutional investor.

Ewing Morris. The head office of Ewing Morris is located at:

1407 Yonge Street, Suite 500
Toronto, Ontario
M4T 1Y7

2.2 State the date of the transaction or other occurrence that triggered the requirement to file this report and briefly describe the transaction or other occurrence.

Since the date of the prior report filed on March 8, 2024 (the “**Prior Report**”), Ewing Morris & Co. Investment Partners Ltd. (“**Ewing Morris**”) on behalf of the EM Fund, sold a total of 948,700 shares of the Reporting Issuer on the Toronto Stock Exchange. The disposition of such Common Shares triggered the requirement to file this report.

2.3 State the name of any joint actors.

Broadview Dark Horse LP (the “EM Fund”) may be considered to be a joint actor of Ewing Morris.

2.4 State that the eligible institutional investor is eligible to file reports under Part 4 in respect of the reporting issuer.

Ewing Morris is eligible to file reports under Part 4 in respect of the Issuer.

Item 3 – Interest in Securities of the Reporting Issuer

3.1 State the designation and the net increase or decrease in the number or principal amount of securities, and in the eligible institutional investor’s security holding percentage in the class of securities, since the last report filed by the eligible institutional investor under Part 4 or the early warning requirements.

As a result of the sales noted above, Ewing Morris now exercises control or direction over 2,315,525 Common Shares, representing a decrease of approximately 3.23% in the number of Common Shares over which Ewing Morris exercises control or direction since the filing of the Prior Report.

3.2 State the designation and number or principal amount of securities and the eligible institutional investor’s securityholding percentage in the class of securities at the end of the month for which the report is made.

As at September 30, 2024, Ewing Morris, on behalf of the EM Fund managed by it, held 2,315,525 Common Shares, representing approximately 8.88% of the outstanding Common Shares of the Reporting Issuer.

3.3 If the transaction involved a securities lending arrangement, state that fact.

Not applicable.

3.4 State the designation and number or principal amount of securities and the percentage of outstanding securities of the class of securities to which this report relates and over which:

(a) the eligible institutional investor, either alone or together with any joint actors, has ownership and control,

The EM Fund has ownership over all of the securities described herein and Ewing Morris has control over all of such securities.

(b) the eligible institutional investor, either alone or together with any joint actors, has ownership but control is held by persons or companies other than the eligible institutional investor or any joint actor, and

Not applicable

- (c) **the eligible institutional investor, either alone or together with any joint actors, has exclusive or shared control but does not have ownership.**

Ewing Morris exercises control or direction over all of the securities referred to in paragraph 3.2 in its capacity as portfolio manager over the EM Fund.

- 3.5 **If the eligible institutional investor or any of its joint actors has an interest in, or right or obligation associated with, a related financial instrument involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the related financial instrument and its impact on the eligible institutional investor's securityholdings.**

Not applicable

- 3.6 **If the eligible institutional investor or any of its joint actors is a party to a securities lending arrangement involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the arrangement including the duration of the arrangement, the number or principal amount of securities involved and any right to recall the securities or identical securities that have been transferred or lent under the arrangement.**

State if the securities lending arrangement is subject to the exception provided in section 5.7 of NI 62-104.

Not applicable

- 3.7 **If the eligible institutional investor or any of its joint actors is a party to an agreement, arrangement or understanding that has the effect of altering, directly or indirectly, the eligible institutional investor's economic exposure to the security of the class of securities to which this report relates, describe the material terms of the agreement, arrangement or understanding.**

Not applicable

Item 4 – Purpose of the Transaction

State the purpose or purposes of the eligible institutional investor and any joint actors for the acquisition or disposition of securities of the reporting issuer. Describe any plans or future intentions which the eligible institutional investor and any joint actors may have which relate to or would result in any of the following:

- (a) **the acquisition of additional securities of the reporting issuer, or the disposition of securities of the issuer;**
- (b) **a sale or transfer of a material amount of the assets of the reporting issuer or any of its subsidiaries;**

- (c) a change in the board of directors or management of the reporting issuer, including any plans or intentions to change the number or term of directors or to fill any existing vacancy on the board;
- (d) a material change in the present capitalization or dividend policy of the reporting issuer;
- (e) a material change in the reporting issuer's business or corporate structure;
- (f) a change in the reporting issuer's charter, bylaws or similar instruments or another action which might impede the acquisition of control of the reporting issuer by any person;
- (g) a class of securities of the reporting issuer being delisted from, or ceasing to be authorized to be quoted on, a marketplace;
- (h) the issuer ceasing to be a reporting issuer in any jurisdiction of Canada;
- (i) a solicitation of proxies from securityholders;
- (j) an action similar to any of those enumerated above.

The securities described herein were purchased for investment purposes only and not for the purpose of exercising control or direction over the Issuer. From time to time, Ewing Morris or the EM Fund may, depending on market and other conditions, acquire or dispose of additional securities of the Reporting Issuer or may continue to hold the securities.

Consistent with its investment intent, Ewing Morris may from time to time engage with members of the board of directors and management of the Reporting Issuer regarding, among other things, the Reporting Issuer, its business and prospects, board composition and potential means for enhancing shareholder value. During the course of such communications, Ewing Morris may advocate or oppose one or more courses of action.

Other than as described above, neither Ewing Morris nor the EM Fund have any intentions with respect to any of the matters enumerated in Item 4.

Item 5 – Agreements, Arrangements, Commitments or Understandings With Respect to Securities of the Reporting Issuer

Describe the material terms of any agreements, arrangements, commitments or understandings between the eligible institutional investor and a joint actor and among those persons and any person with respect to securities of the class of securities to which this report relates, including but not limited to the transfer or the voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. Include such information for any of the securities that are pledged or otherwise subject to a contingency, the occurrence of which would give another person voting power or

investment power over such securities except that disclosure of standard default and similar provisions contained in loan agreements need not be included.

None

Item 6 – Change in Material Fact

If applicable, describe any change in a material fact set out in a previous report filed by the eligible institutional investor under the early warning requirements or Part 4 in respect of the reporting issuer’s securities.

Not applicable

Item 7 – Certification

The eligible institutional investor must certify that the information in this report is true and complete in every respect. In the case of an agent, the certification is based on the agent’s best knowledge, information and belief but the eligible institutional investor is still responsible for ensuring that the information filed by the agent is true and complete.

This report must be signed by each person on whose behalf the report is filed or his or her authorized representative.

It is an offence to submit information that, in a material respect and at the time and in the light of the circumstances in which it is submitted, is misleading or untrue.

Certificate

The certificate must state the following:

I, as the eligible institutional investor, certify, or I, as the agent filing this report on behalf of the eligible institutional investor, certify to the best of my knowledge, information and belief, that the statements made in this report are true and complete in every respect.

.....October 9, 2024.....
Date

..... “Breann Kelly”
Signature

.....Breann Kelly, COO & CCO.....
Name/Title